SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer
JAMA Network Open · 25.02.2026 · 9 (2) · e260146
DOI: 10.1001/jamanetworkopen.2026.0146 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Network Open, online erschienen am 25.02.2026. Verfasst von Cristian Udovicich und 20 weiteren Autor:innen. Beteiligte Einrichtung: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Radiosurgery. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Stereotactic body radiotherapy (SBRT) and high–dose-rate brachytherapy monotherapy (HDR-BT) are options for intermediate-risk prostate cancer. However, no prospective evidence is available to compare these modalities.
Objective
To compare the biochemical failure (BCF), late patient-reported quality of life (PR-QoL), and acute and late adverse events (AEs) associated with SBRT and HDR-BT using prospective data. Data Sources This was an individual patient data post hoc pooled analysis of 5 prospective trials with recruitment from 2010 to 2018. Statistical analyses were performed in September 2024. Study Selection This was a post hoc analysis of these 5 sprospective trials. Eligibility criteria comprised men with intermediate-risk prostate cancer undergoing 5- or 2-fraction SBRT or 2-fraction HDR-BT. No androgen deprivation therapy was permitted. Data Extraction and Synthesis Baseline patient and clinicopathological characteristics were requested. Main Outcomes and Measures BCF, a minimal clinically important change on the PR-QoL, and clinician-reported AEs were the main outcomes.
Results
After a median (IQR) follow-up of 9.5 (5.5-10.6) years, 247 men met the eligibility criteria, including 180 men undergoing SBRT (72.8%; mean [SD] age, 69.5 [6.7] years) and 67 men undergoing HDR-BT (27.1%; mean [SD] age, 66.0 [6.5] years). HDR-BT was associated with increased BCF. At 5 years, BCF was 7.8% (95% CI, 1.0%-14.6%) for HDR compared with 3.0% (95% CI, 0.4%-5.6%) for SBRT. At 10 years, BCF was 38.0% (95% CI, 19.8%-56.1%) for HDR compared with 10.4% (95% CI, 4.3%-16.6%) for SBRT ( P < .001). The HDR-BT cohort had a significantly higher incidence of acute grade 2 or greater genitourinary AEs compared with SBRT (50 men [74.6%] vs 31 men [51.7%]; P = .007). There were no significant differences in any other acute or late AEs or late PR-QoL. Conclusions and Relevance This post hoc pooled analysis reports a long-term comparison of SBRT and HDR-BT using prospective data. SBRT had significantly lower BCF and acute genitourinary AEs, and there was no significant difference in late PR-QoL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
- GenesisCare Radiation Oncology, Melbourne, Victoria, Australia.
- Alfred Health Radiation Oncology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
- BC Cancer, Kelowna, British Columbia, Canada.
- Division of Radiation Oncology, Verspeeten Family Cancer Center, Western University, London, Ontario, Canada.
Zitieren
APA
Udovicich, C., Cheung, P., Chu, W., Chung, H., Detsky, J., Liu, S., Morton, G., Tseng, C. L., Vesprini, D., Hudson, J. M., Ong, W. L., Kennedy, T., Helou, J., Davidson, M., Ravi, A., McGuffin, M., Zhang, L., Mamedov, A., Deabreu, A., …, & Loblaw, A. (2026). SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer. JAMA Network Open, 9(2), e260146. https://doi.org/10.1001/jamanetworkopen.2026.0146
Vancouver
Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, et al. SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer. JAMA Network Open. 2026;9(2):e260146. doi:10.1001/jamanetworkopen.2026.0146
BibTeX
@article{Udovicich2026,
author = {Udovicich, Cristian and Cheung, Patrick and Chu, William and Chung, Hans and Detsky, Jay and Liu, Stanley and Morton, Gerard and Tseng, Chia-Lin and Vesprini, Danny and Hudson, John M and Ong, Wee Loon and Kennedy, Thomas and Helou, Joelle and Davidson, Melanie and Ravi, Ananth and McGuffin, Merrylee and Zhang, Liying and Mamedov, Alexandre and Deabreu, Andrea and Kulasingham-Poon, Meghan and Loblaw, Andrew},
title = {SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {2},
pages = {e260146},
doi = {10.1001/jamanetworkopen.2026.0146}
}
EUVIMED